Role of magnetic resonance imaging in the management of patients with multiple myeloma: A consensus statement

Meletios A. Dimopoulos, Jens Hillengass, Saad Usmani, Elena Zamagni, Suzanne Lentzsch, Faith E. Davies, Noopur Raje, Orhan Sezer, Sonja Zweegman, Jatin Shah, Ashraf Badros, Kazuyuki Shimizu, Philippe Moreau, Chor Sang Chim, Juan José Lahuerta, Jian Hou, Artur Jurczyszyn, Hartmut Goldschmidt, Pieter Sonneveld, Antonio PalumboHeinz Ludwig, Michele Cavo, Bart Barlogie, Kenneth Anderson, G. David Roodman, S Vincent Rajkumar, Brian G M Durie, Evangelos Terpos

Research output: Contribution to journalArticle

155 Citations (Scopus)

Abstract

Purpose: The aim of International Myeloma Working Group was to develop practical recommendations for the use of magnetic resonance imaging (MRI) in multiple myeloma (MM). Methods: An interdisciplinary panel of clinical experts on MM and myeloma bone disease developed recommendations for the value of MRI based on data published through March 2014. Recommendations: MRI has high sensitivity for the early detection of marrow infiltration by myeloma cells compared with other radiographic methods. Thus, MRI detects bone involvement in patients with myeloma much earlier than the myeloma-related bone destruction, with no radiation exposure. It is the gold standard for the imaging of axial skeleton, for the evaluation of painful lesions, and for distinguishing benign versus malignant osteoporotic vertebral fractures. MRI has the ability to detect spinal cord or nerve compression and presence of soft tissue masses, and it is recommended for the workup of solitary bone plasmacytoma. Regarding smoldering or asymptomatic myeloma, all patients should undergo whole-body MRI (WB-MRI; or spine and pelvic MRI if WB-MRI is not available), and if they have > one focal lesion of a diameter > 5 mm, they should be considered to have symptomatic disease that requires therapy. In cases of equivocal small lesions, a second MRI should be performed after 3 to 6 months, and if there is progression on MRI, the patient should be treated as having symptomatic myeloma. MRI at diagnosis of symptomatic patients and after treatment (mainly after autologous stem-cell transplantation) provides prognostic information; however, to date, this does not change treatment selection.

Original languageEnglish (US)
Pages (from-to)657-664
Number of pages8
JournalJournal of Clinical Oncology
Volume33
Issue number6
DOIs
StatePublished - Feb 20 2015

Fingerprint

Multiple Myeloma
Magnetic Resonance Imaging
Bone and Bones
Spinal Nerves
Osteoporotic Fractures
Plasmacytoma
Bone Diseases
Stem Cell Transplantation
Skeleton
Spinal Cord
Spine
Therapeutics
Bone Marrow

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Dimopoulos, M. A., Hillengass, J., Usmani, S., Zamagni, E., Lentzsch, S., Davies, F. E., ... Terpos, E. (2015). Role of magnetic resonance imaging in the management of patients with multiple myeloma: A consensus statement. Journal of Clinical Oncology, 33(6), 657-664. https://doi.org/10.1200/JCO.2014.57.9961

Role of magnetic resonance imaging in the management of patients with multiple myeloma : A consensus statement. / Dimopoulos, Meletios A.; Hillengass, Jens; Usmani, Saad; Zamagni, Elena; Lentzsch, Suzanne; Davies, Faith E.; Raje, Noopur; Sezer, Orhan; Zweegman, Sonja; Shah, Jatin; Badros, Ashraf; Shimizu, Kazuyuki; Moreau, Philippe; Chim, Chor Sang; Lahuerta, Juan José; Hou, Jian; Jurczyszyn, Artur; Goldschmidt, Hartmut; Sonneveld, Pieter; Palumbo, Antonio; Ludwig, Heinz; Cavo, Michele; Barlogie, Bart; Anderson, Kenneth; Roodman, G. David; Rajkumar, S Vincent; Durie, Brian G M; Terpos, Evangelos.

In: Journal of Clinical Oncology, Vol. 33, No. 6, 20.02.2015, p. 657-664.

Research output: Contribution to journalArticle

Dimopoulos, MA, Hillengass, J, Usmani, S, Zamagni, E, Lentzsch, S, Davies, FE, Raje, N, Sezer, O, Zweegman, S, Shah, J, Badros, A, Shimizu, K, Moreau, P, Chim, CS, Lahuerta, JJ, Hou, J, Jurczyszyn, A, Goldschmidt, H, Sonneveld, P, Palumbo, A, Ludwig, H, Cavo, M, Barlogie, B, Anderson, K, Roodman, GD, Rajkumar, SV, Durie, BGM & Terpos, E 2015, 'Role of magnetic resonance imaging in the management of patients with multiple myeloma: A consensus statement', Journal of Clinical Oncology, vol. 33, no. 6, pp. 657-664. https://doi.org/10.1200/JCO.2014.57.9961
Dimopoulos, Meletios A. ; Hillengass, Jens ; Usmani, Saad ; Zamagni, Elena ; Lentzsch, Suzanne ; Davies, Faith E. ; Raje, Noopur ; Sezer, Orhan ; Zweegman, Sonja ; Shah, Jatin ; Badros, Ashraf ; Shimizu, Kazuyuki ; Moreau, Philippe ; Chim, Chor Sang ; Lahuerta, Juan José ; Hou, Jian ; Jurczyszyn, Artur ; Goldschmidt, Hartmut ; Sonneveld, Pieter ; Palumbo, Antonio ; Ludwig, Heinz ; Cavo, Michele ; Barlogie, Bart ; Anderson, Kenneth ; Roodman, G. David ; Rajkumar, S Vincent ; Durie, Brian G M ; Terpos, Evangelos. / Role of magnetic resonance imaging in the management of patients with multiple myeloma : A consensus statement. In: Journal of Clinical Oncology. 2015 ; Vol. 33, No. 6. pp. 657-664.
@article{b36f6b684a58421d9cb1f53599b8cb7f,
title = "Role of magnetic resonance imaging in the management of patients with multiple myeloma: A consensus statement",
abstract = "Purpose: The aim of International Myeloma Working Group was to develop practical recommendations for the use of magnetic resonance imaging (MRI) in multiple myeloma (MM). Methods: An interdisciplinary panel of clinical experts on MM and myeloma bone disease developed recommendations for the value of MRI based on data published through March 2014. Recommendations: MRI has high sensitivity for the early detection of marrow infiltration by myeloma cells compared with other radiographic methods. Thus, MRI detects bone involvement in patients with myeloma much earlier than the myeloma-related bone destruction, with no radiation exposure. It is the gold standard for the imaging of axial skeleton, for the evaluation of painful lesions, and for distinguishing benign versus malignant osteoporotic vertebral fractures. MRI has the ability to detect spinal cord or nerve compression and presence of soft tissue masses, and it is recommended for the workup of solitary bone plasmacytoma. Regarding smoldering or asymptomatic myeloma, all patients should undergo whole-body MRI (WB-MRI; or spine and pelvic MRI if WB-MRI is not available), and if they have > one focal lesion of a diameter > 5 mm, they should be considered to have symptomatic disease that requires therapy. In cases of equivocal small lesions, a second MRI should be performed after 3 to 6 months, and if there is progression on MRI, the patient should be treated as having symptomatic myeloma. MRI at diagnosis of symptomatic patients and after treatment (mainly after autologous stem-cell transplantation) provides prognostic information; however, to date, this does not change treatment selection.",
author = "Dimopoulos, {Meletios A.} and Jens Hillengass and Saad Usmani and Elena Zamagni and Suzanne Lentzsch and Davies, {Faith E.} and Noopur Raje and Orhan Sezer and Sonja Zweegman and Jatin Shah and Ashraf Badros and Kazuyuki Shimizu and Philippe Moreau and Chim, {Chor Sang} and Lahuerta, {Juan Jos{\'e}} and Jian Hou and Artur Jurczyszyn and Hartmut Goldschmidt and Pieter Sonneveld and Antonio Palumbo and Heinz Ludwig and Michele Cavo and Bart Barlogie and Kenneth Anderson and Roodman, {G. David} and Rajkumar, {S Vincent} and Durie, {Brian G M} and Evangelos Terpos",
year = "2015",
month = "2",
day = "20",
doi = "10.1200/JCO.2014.57.9961",
language = "English (US)",
volume = "33",
pages = "657--664",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "6",

}

TY - JOUR

T1 - Role of magnetic resonance imaging in the management of patients with multiple myeloma

T2 - A consensus statement

AU - Dimopoulos, Meletios A.

AU - Hillengass, Jens

AU - Usmani, Saad

AU - Zamagni, Elena

AU - Lentzsch, Suzanne

AU - Davies, Faith E.

AU - Raje, Noopur

AU - Sezer, Orhan

AU - Zweegman, Sonja

AU - Shah, Jatin

AU - Badros, Ashraf

AU - Shimizu, Kazuyuki

AU - Moreau, Philippe

AU - Chim, Chor Sang

AU - Lahuerta, Juan José

AU - Hou, Jian

AU - Jurczyszyn, Artur

AU - Goldschmidt, Hartmut

AU - Sonneveld, Pieter

AU - Palumbo, Antonio

AU - Ludwig, Heinz

AU - Cavo, Michele

AU - Barlogie, Bart

AU - Anderson, Kenneth

AU - Roodman, G. David

AU - Rajkumar, S Vincent

AU - Durie, Brian G M

AU - Terpos, Evangelos

PY - 2015/2/20

Y1 - 2015/2/20

N2 - Purpose: The aim of International Myeloma Working Group was to develop practical recommendations for the use of magnetic resonance imaging (MRI) in multiple myeloma (MM). Methods: An interdisciplinary panel of clinical experts on MM and myeloma bone disease developed recommendations for the value of MRI based on data published through March 2014. Recommendations: MRI has high sensitivity for the early detection of marrow infiltration by myeloma cells compared with other radiographic methods. Thus, MRI detects bone involvement in patients with myeloma much earlier than the myeloma-related bone destruction, with no radiation exposure. It is the gold standard for the imaging of axial skeleton, for the evaluation of painful lesions, and for distinguishing benign versus malignant osteoporotic vertebral fractures. MRI has the ability to detect spinal cord or nerve compression and presence of soft tissue masses, and it is recommended for the workup of solitary bone plasmacytoma. Regarding smoldering or asymptomatic myeloma, all patients should undergo whole-body MRI (WB-MRI; or spine and pelvic MRI if WB-MRI is not available), and if they have > one focal lesion of a diameter > 5 mm, they should be considered to have symptomatic disease that requires therapy. In cases of equivocal small lesions, a second MRI should be performed after 3 to 6 months, and if there is progression on MRI, the patient should be treated as having symptomatic myeloma. MRI at diagnosis of symptomatic patients and after treatment (mainly after autologous stem-cell transplantation) provides prognostic information; however, to date, this does not change treatment selection.

AB - Purpose: The aim of International Myeloma Working Group was to develop practical recommendations for the use of magnetic resonance imaging (MRI) in multiple myeloma (MM). Methods: An interdisciplinary panel of clinical experts on MM and myeloma bone disease developed recommendations for the value of MRI based on data published through March 2014. Recommendations: MRI has high sensitivity for the early detection of marrow infiltration by myeloma cells compared with other radiographic methods. Thus, MRI detects bone involvement in patients with myeloma much earlier than the myeloma-related bone destruction, with no radiation exposure. It is the gold standard for the imaging of axial skeleton, for the evaluation of painful lesions, and for distinguishing benign versus malignant osteoporotic vertebral fractures. MRI has the ability to detect spinal cord or nerve compression and presence of soft tissue masses, and it is recommended for the workup of solitary bone plasmacytoma. Regarding smoldering or asymptomatic myeloma, all patients should undergo whole-body MRI (WB-MRI; or spine and pelvic MRI if WB-MRI is not available), and if they have > one focal lesion of a diameter > 5 mm, they should be considered to have symptomatic disease that requires therapy. In cases of equivocal small lesions, a second MRI should be performed after 3 to 6 months, and if there is progression on MRI, the patient should be treated as having symptomatic myeloma. MRI at diagnosis of symptomatic patients and after treatment (mainly after autologous stem-cell transplantation) provides prognostic information; however, to date, this does not change treatment selection.

UR - http://www.scopus.com/inward/record.url?scp=84923190533&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923190533&partnerID=8YFLogxK

U2 - 10.1200/JCO.2014.57.9961

DO - 10.1200/JCO.2014.57.9961

M3 - Article

C2 - 25605835

AN - SCOPUS:84923190533

VL - 33

SP - 657

EP - 664

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 6

ER -